<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02683616</url>
  </required_header>
  <id_info>
    <org_study_id>AZV15_30155A</org_study_id>
    <nct_id>NCT02683616</nct_id>
  </id_info>
  <brief_title>Fatty Acid Metabolism in Obstructive Sleep Apnea (FAMOSA)</brief_title>
  <acronym>FAMOSA</acronym>
  <official_title>Fatty Acid Metabolism in Obstructive Sleep Apnea (FAMOSA)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Faculty Hospital Kralovske Vinohrady</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Faculty Hospital Kralovske Vinohrady</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Obstructive sleep apnea syndrome (OSA) is a disease affecting 5-15% of population and 50-80%
      of type 2 diabetes mellitus (T2DM) and obese subjects. OSA causally contributes to the
      development of glucose intolerance and T2DM. The project is targeting the gap in providing
      effective treatment of metabolic impairments associated with OSA, particularly T2DM. In
      contrast to proved benefits of OSA treatment with CPAP (continuous positive airway pressure)
      on cardiovascular morbidity/mortality, studies on the impact of CPAP on diabetes control are
      disappointing. In fact, OSA-induced metabolic impairments might not be reversible with CPAP
      treatment, as investigators suggested recently. Clearly, the search for additional
      treatments, probably pharmacological, is warranted. Investigators hypothesize that elevated
      levels of free fatty acids (FFA), as detected in OSA patients, are linking OSA with the T2DM
      development. The aim of the study is to target adipose tissue and muscle dysfunction leading
      to elevated FFA and develop thus novel pharmacological treatments based on lipolysis
      inhibition and stimulation of FFA oxidation.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>April 2015</start_date>
  <completion_date type="Anticipated">December 2019</completion_date>
  <primary_completion_date type="Anticipated">December 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Glycerol release (lipolysis) in adipose tissue</measure>
    <time_frame>Baseline and 6 months</time_frame>
    <description>Changes in interstitial glycerol concentration in adipose tissue</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Palmitate oxidation in skeletal muscle</measure>
    <time_frame>Baseline and 6 months</time_frame>
    <description>Changes in palmitate oxidation in muscle biopsies measured ex vivo</description>
  </primary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Obstructive Sleep Apnea</condition>
  <condition>Fatty Acid Metabolism</condition>
  <condition>Continuous Positive Airway Pressure</condition>
  <arm_group>
    <arm_group_label>OSA + T2DM</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>CPAP treatment</description>
  </arm_group>
  <arm_group>
    <arm_group_label>OSA no T2DM</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>CPAP treatment</description>
  </arm_group>
  <arm_group>
    <arm_group_label>T2DM no OSA</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Standard care</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Healthy controls no Ã“SA</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>no intervention</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>CPAP</intervention_name>
    <description>Continuous Positive Airway Pressure in cases of moderate/severe OSA</description>
    <arm_group_label>OSA + T2DM</arm_group_label>
    <arm_group_label>OSA no T2DM</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Type 2 Diabetes mellitus

          -  Age 18 - 85 years

          -  BMI 22-40 kg/m2

          -  moderate or severe OSA diagnosed by home sleep study

        Exclusion Criteria:

          -  treatment with insulin

          -  other acute or chronic endocrine or inflammatory disease
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Jan Polak, MD, PhD</last_name>
    <phone>+420267162710</phone>
    <email>jan.polak@lf3.cuni.cz</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Jan Gojda, MD, PhD</last_name>
    <phone>+420267168144</phone>
  </overall_contact_backup>
  <location>
    <facility>
      <name>FN Kralovske Vinohrady</name>
      <address>
        <city>Prague</city>
        <zip>10034</zip>
        <country>Czechia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jan Polak, MD, PhD</last_name>
      <phone>+420267162710</phone>
      <email>jan.polak@lf3.cuni.cz</email>
    </contact>
    <contact_backup>
      <last_name>Jan Gojda, MD, PhD</last_name>
      <phone>+420267168144</phone>
      <email>jan.gojda@lf3.cuni.cz</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Czechia</country>
  </location_countries>
  <removed_countries>
    <country>Czech Republic</country>
  </removed_countries>
  <verification_date>February 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 9, 2016</study_first_submitted>
  <study_first_submitted_qc>February 11, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 17, 2016</study_first_posted>
  <last_update_submitted>February 6, 2018</last_update_submitted>
  <last_update_submitted_qc>February 6, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">February 7, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Faculty Hospital Kralovske Vinohrady</investigator_affiliation>
    <investigator_full_name>Jan Polak</investigator_full_name>
    <investigator_title>Associate Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Apnea</mesh_term>
    <mesh_term>Sleep Apnea Syndromes</mesh_term>
    <mesh_term>Sleep Apnea, Obstructive</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

